Final height and puberty in 40 patients after antileukaemic treatment during childhood

European Journal of Pediatrics

Volumn 156, Issue 4, 1997, Pages 272-276

  Mohnike, K ^a   Dorffel W ^b   Timme, J ^c   Kluba, U ^a   Aumann, V ^a   Vorwerk, P ^a   Mittler, U ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HELIOS Klinikum Berlin   (Germany)

^c Walter Friedrich Krankenhaus Olvenstedt   (Germany)

Author keywords

Chemotherapy; Cranial irradiation; Growth; Leukaemia; Non Hodgkin lymphoma

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BODY HEIGHT; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILD; FEMALE; GROWTH DISORDER; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUBERTY;

6-MERCAPTOPURINE; ADOLESCENT; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GROWTH; GROWTH DISORDERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LONGITUDINAL STUDIES; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; PUBERTY;

EID: 0030900002     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310050599     Document Type: Article

References (33)

1. Bielack SS, Beck JD, Winkler K (1995) Spätfolgen nach Krebsbehandlung im Kindesalter. Monatsschr Kinderheilkd 143:649-657
2. Bourguignon JP, Gerard A, Alvarez ML, Franchimont P (1994) The hypothalamic mechanism of the onset of puberty. In: Savage M, Bourguignon JP, Grossman AB (eds) Frontiers in paediatric neuroendocrinology. Blackwell, Oxford, pp 1-8
3. Brämswig JH, Zielinski G, Schellong G (1990) Adult height, target height and siblings adult height in 107 patients treated for acute lymphoblastic leukaemia (ALL). Comparison of the effects of four different chemotherapy regimens and different doses of cranial irradiation (abstract). Horm Res 33:32
4. Brann DW (1995) Glutamate: a major excitatory transmitter in neuroendocrine regulation. Neuroendocrinology 61:213-225
5. Cicognani A, Cacciari E, Rosito P, Mancini AF, Carla G, Mandini M, Paolucci G (1994) Longitudinal growth and final height in long-term survivors of childhood leukaemia. Eur J Pediatr 153:726-730
6. Crowne EC, Moore C, Wallace WH, Ogilvy Stuart AL, Addison GM, Morris Jones PH, Shalet SM: (1992) A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation. Clin Endocrinol Oxf 36:59-68
7. Davies HA, Didcock E, Didi M, Ogilvy Stuart A, Wales JK, Shalet SM: (1994) Disproportionate short stature after cranial irradiation and combination chemotherapy for leukaemia. Arch Dis Child 70:472-475
8. De Schepper J, Hachdimi-Idrissi S, Louis O, Maurus R, Otten J (1994) Bone metabolism and mineralisation after cytotoxic chemotherapy including ifosfamide. Arch Dis Child 71:346-348
9. Engelhardt L, Willers B, Pelz L (1995) Sexual maturation in east german girls. Acta Paediatr 84:1362-1365
10. Grumbach MM, Kaplan SL (1990) The neuroendocrinology of human puberty: an ontogenetic perspective. In: Grumbach MM, Sizonenko PC, Aubert ML (eds) Control of the onset of puberty. Williams and Wilkins, Baltimore, pp 1-68
11. Hokken Koelega AC, Doom JW van, Hahlen K, Stijnen T, Muinck Keizer Schrama SM de, Drop SL (1993) Long-term effects of treatment for acute lymphoblastic leukaemia with and without cranial irradiation on growth and puberty: a comparative study. Pediatr Res 33:577-582
12. Katz JA, Pollock BH, Jacaruso D, Morad A (1993) Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. J Pediatr 123:546-552
13. Kirk JA, Stevens MM, Menser MA, Tink A, Raghupathy P, Cowell CT, Bergin M, Vines RH, Silink M (1987) Growth failure and growth hormone deficiency after treatment for acute lymphoblastic leukemia. Lancet I:190-193
14. Lannering B, Marky I, Mellander L, Albertsson-Wikland K (1988) Growth hormone secretion and response to growth hormone therapy after treatment for brain tumour. Acta Paediatr Scand [Suppl] 343:146-151
15. Moell C, Garwicz S (1995) Influence of treatment modalities on prepubertal growth in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 12:425-427
16. Moell C, Garwicz S, Westgren U, Wiebe T, Albertsson-Wikland K (1988) Blunted pubertal growth after leukaemia: a new pattern of growth hormone insufficiency. Horm Res 30:68-71
17. Moell C, Marky I, Hovi L, Kristinsson J, Rix M, Moe PJ, Garwicz S: (1994) Cerebral irradiation causes blunted pubertal growth in girls treated for acute leukemia. Med Pediatr Oncol 22:375-379
18. Mohnike K, Mittler U, Kluba U, Kröning G, Kapitza W, Aumann V (1989) Recent ALL-protocol prevents loss in height using less intensive maintenance chemotherapy (abstract). Horm Res 31:47
19. Ogilvy Stuart AL, Clayton PE, Shalet SM (1994) Cranial irradiation and early puberty [see comments]. J Clin Endocrinol Metab 78:1282-1286
20. Papadakis V, Tan C, Heller G, Sklar C (1996) Growth and final height after treatment for childhood Hodgkin disease. J Pediatr Hematol Oncol 18:272-276
21. Prader A, Largo RH, Molinari L, Issler C (1989) Physical growth of swiss children form birth to 20 years of age. The First Zurich longitudinal study of growth and development. Helv Paediatr Acta [Suppl] 52:1-125
22. Reinken L, Van Oost G (1992) Longitudinale Körperentwicklung gesunder Kinder von 0 bis 18 Jahren. Klin Pädiatr 204:129-133
23. Riehm H, Feikert H-J, Schrappe M, Henze G, Schellong G: (1987) Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. In: Büchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J (eds) Acute leukemias. Prognostic factors and treatment strategies. Springer-Verlag, Berlin Heidelberg New York, pp 139-146
24. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G (1990) Results and significance of six randomized trials in four consecutive ALL-BFM studies. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias II. Springer-Verlas, Berlin Heidelberg New York, pp 439-450
25. Rivera GK, Crist WM (1995) Acute lymphoblastic leukemia. In: Handin RI, Lux SE, Stossel TP (eds) Blood. Principles and practice of hematology. Lippincot, Philadelphia, pp 743-782
26. Rodgers J, Britton PG, Morris RG, Kernahan J, Craft AW (1992) Memory after treatment for acute lymphoblastic leukemia. Arch Dis Child 67:266-268
27. Sato J, Ninomiya T, Tsuda Y, Komazawa M, Nagata K, Iwai A, Nishikawa K, Maeda H, Ohmiya A, Ohta M, et al (1992) Analysis of growth failure in children treated for acute lymphoblastic leukemia. Int J Hematol 56:205-212
28. Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ (1991) Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol 9:400-405
29. Stubberfield TG, Byrne GC, Jones TW (1995) Growth and growth hormone secretion after treatment for acute lymphoblastic leukemia in childhood. J Pediatr Hematol Oncol 17:167-171
30. Uruena M, Stanhope R, Chessells JM, Leiper AD (1991) Impaired pubertal growth in acute lymphoblastic leukaemia. Arch Dis Child 66:1403-1407
31. Van der Does-VandenBerg A, Vaan GAM de, Weerden JF van, Hählen K, Weel-Sipman M van, Veerman AJP (1995) Late effects among long-term survivors of childhood acute leukaemia in the Netherlands: a Dutch childhood leukemia study group report. Pediatr Res 38:802-807
32. Van Dongen-Melman JEWM, Hokken Koelega AC, Hählen K, DeGroot A, Tromp CG, Egeler RM (1995) Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 38:86-90
33. 2 protocol chemotherapy. Cancer 45:3034-3039